|Synonyms||(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(2,6-diethylanilino)-2-oxoethyl]-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid; (2R-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-(2-(2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid; A 192621; A-192621; A192621|
|Description||A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.|
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
BMS-248360 is a first orally active generation dual action receptor antagonist. BMS-248360 antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50 = ...
RO462005 is an endothelin receptor selective agonist.
BMS 182874 Hydrochloride
This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM...
Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...
BMS-187308, a sulfonamide derivative, has been found to be an endothelin-A (ETA) antagonist that was once studied about its activity against pressor effect in r...
Tezosentan, also known as RO 610612 and Veletri, is a potent dual endothelian (ETA/ETB) receptor antagonist optimized from Bosentan (B675900). It acts as a vaso...
Macitentan n-butyl analogue
Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.
Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmente...
Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No devel...
atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective anta...
The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.
Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...
Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.